Immune checkpoint protein B7-H3 (CD276) has garnered increasing attention as a cancer immunotherapy target. Despite the absence of a definitively identified receptor, B7-H3 is implicated in multiple mechanisms of tumor progression. As a cancer biomarker, it is overexpressed in numerous cancer types and is often associated with poor prognosis. B7-H3 is currently the target of numerous immunotherapeutic strategies, and clinical trials are underway in various cancer types. This review provides an updated summary of the current body of knowledge regarding immune checkpoint protein B7-H3 and cancer therapies targeting it, highlighting its demonstrated promise as a cancer immunotherapy target, the need for further investigation into the regulation and mechanisms of B7-H3 and its associated pathways, and therapeutic progress.
No takes yet. Share an insight, caveat, or question.
Smith et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: